tbuckley/cabot-search huggingface dataset:
P137 THE EXPRESSION OF NKG2D-LIGANDS BY ACTIVATED CD4 T CELLS RENDERS THEM SUSCEPTIBLE TO NK CELL REGULATION IN CHRONIC HEPATITIS B (CHB)
Authors: W.-C. Huang, D. Peppa, N. Easom, X.-Z. Tan, C. Chang, J. Trowsdale, U. Gill, P. Kennedy, M. Maini
Journal: Journal of Hepatology (2014)
Pedunculated Hepatic Hemangioma Identified on Tc-99m DTPA-HSA Scintigraphy
Authors: YOSHIHIRO NISHIYAMA, YUKA YAMAMOTO, KOTARO FUKUNAGA, YUKO FUKUDA, KATASHI SATOH, MOTOOMI OHKAWA, MASATADA TANABE
Journal: Clinical Nuclear Medicine (1999)

A patient had a pedunculated hepatic hemangioma originating from the lateral portion of the left lobe that radiologically mimicked a submucosal gastric tumor. The characteristic perfusion blood-pool mismatch with hemangiomas was shown in the left upper quadrant on Tc-99m DTPA-HSA scintigraphy. Histopathologic analysis revealed a giant cavernous hemangioma.
Serendipitous Diagnosis of Multiple Myeloma During Sestamibi Myocardial Perfusion Imaging
Authors: JEAN LETTE, MICHEL CERINO, STÉPHANE DEMARIA, MARIE-CLAIRE EYBALIN, ANDRÉ LEVASSEUR
Journal: Clinical Nuclear Medicine (2002)

LETTE, JEAN M.D.; CERINO, MICHEL M.D.; DEMARIA, STÉPHANE C.N.M.T.; EYBALIN, MARIE-CLAIRE M.D.; LEVASSEUR, ANDRÉ M.D. Author Information
Abstract LB-134: mTORC2 regulates the amount of cell surface receptors via its role in protein processing.
Authors: Aixa Navia, Chang-chih Wu, Wonjun Oh, Chou Po-Chien, Michael A. DeStefano, Guy Werlen, Estela Jacinto
Journal: Cancer Research (2013)

Abstract Signals from cell surface receptors can become altered in cancer due to increased receptor levels. Little is known on how abnormal protein production and quality control may contribute to receptor amplification and tumorigenesis. The mammalian target of rapamycin (mTOR) complex 2 (mTORC2) associates with translating ribosomes and is involved in protein processing. Association of mTORC2 with ribosomes is increased in tumor cells with enhanced PI3K signaling. We found that inhibition of mTORC2 decreases the expression of ErbB1 and CD147 in breast cancer cells. Whereas upregulation of ErbB1 (EGFR1) expression and/or signaling is associated with increased proliferation in breast cancer, CD147 (basigin; EMMPRIN) is linked to tumor metastasis. In mTORC2-disrupted cells, ErbB1 and CD147 have defective expression and processing. Glucose-starved breast cancer cells undergo misprocessing of CD147 along with a decreased expression of mature receptors. Our findings suggest that mTORC2 plays a role in receptor processing and could therefore control cell proliferation via regulation of the amount of growth factor receptors in the cell surface. Citation Format: Aixa Navia, Chang-chih Wu, Wonjun Oh, Chou Po-Chien, Michael A. DeStefano, Guy Werlen, Estela Jacinto. mTORC2 regulates the amount of cell surface receptors via its role in protein processing. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-134. doi:10.1158/1538-7445.AM2013-LB-134
THU0270 Decreased Risk for Severe Persisting Pain in Elderly Patients with Early Rheumatoid Arthritis – Results from the Swedish Population-Based EIRA and SRQ Register
Authors: M.E. Sandberg, R. Altawil, L. Alfredsson, L. Klareskog, S. Saevarsdottir, J. Lampa
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Pain is common in rheumatoid arthritis (RA), and a significant portion of patients report pain also after adequate disease suppression and achievement of low detectable inflammation. In order to optimize pain and antirheumatic treatment, there is a need for early identification of patients with pain that is independent of inflammation. <h3>Objectives</h3> To investigate the prevalence and potential predictors for a severe persistent pain phenotype of early RA. <h3>Methods</h3> We used the cases from a Swedish population-based case-control study; the EIRA study; in total, 1802 incident RA patients aged 18-70 was recruited 1996-2009 and followed in the Swedish Rheumatology Quality register for up to 5 years. We defined RA severe persisting pain phenotype as having pain measured on a visual-analog scale (VAS) ≥50 at diagnosis and VAS ≥50 together with a CRP &lt;10 at the 2-year follow-up visit. Logistic regression was used to calculate the effect of sex, age at diagnosis and calendar period of diagnosis on this outcome, we also further adjusted our model for smoking and socioeconomic status (based on education). <h3>Results</h3> Out of 1733 patients with data on both time points we found 123 patients (7.1%) with severe pain persisting phenotype. Sex and calendar period of diagnosis did not affect this condition significantly, but age at diagnosis did. Compared to the reference group (aged 50-60) the oldest age group (aged 65-70) had a lowered risk (OR=0.54 [95%CI: 0.29-1.00]), also for the youngest patients (aged &lt;40), there was an indication of a lower risk, albeit not statistically significant (OR=0.58 [95%CI: 0.33-1.04]). Further adjustments for smoking and socioeconomic status enhanced the effect of older age (for patients aged 65-70 the OR=0.46 [95%CI: 0.24-0.90], smoking and socioeconomic status were not significant predictors themselves. There were no significant differences between the age groups concerning pain at diagnosis or correlation between pain and DAS28, either at diagnosis or after 2 years. <h3>Conclusions</h3> In a population-based cohort of early RA patients, the prevalence of severe persisting pain was 7.1%. Older patients seem to have a lower risk for development of severe persisting pain in early RA, independent of sex, calendar period of diagnosis, smoking and socioeconomic status. These data indicate that age is important to consider in further investigations of non-inflammatory coupled pain development in RA. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3348
PROGNOSTIC IMPORTANCE OF SELF-REPORTED DYSPNEA FOR CARDIOVASCULAR OUTCOMES IN PERSONS WITHOUT PREVALENT CARDIOVASCULAR OR PULMONARY DISEASE: THE ATHEROSCLEROSIS RISK IN COMMUNITIES STUDY
Authors: Mario Santos, Dalane Kitzman, Kunihiro Matsushita, Laura Loehr, Carla Sueta, Amil Shah
Journal: Journal of the American College of Cardiology (2016)
AB1093 Efficacy and safety of steroid injections for shoulder pain
Authors: F. Teixeira, D. Peixoto, C. Afonso, D. Araújo
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Shoulder pain has been found to be the second most frequent acute musculoskeletal complaint presenting in general practice and the third most common site of musculoskeletal pain in the community. Approximately 10% of people will have one or more episodes of shoulder pain during their lifetime. Although local steroid injections are one of the most common treatments, there is no strong evidence to support their use and they have potential adverse effects. The optimum timing of steroid injections is also still unclear. <h3>Objectives</h3> To assess the efficacy and safety of steroid injections for patients with shoulder pain at six, 12 and 18 months after subacromial steroid injection, correlate ultrasound changes and with time course of shoulder pain and treatment outcomes. <h3>Methods</h3> In a prospective study, 86 patients with shoulder pain were evaluated for demographic and clinical data and a visual analog scale (VAS) for pain. In all was performed a shoulder ultrasound. Ultrasound operator evaluated for the presence of rotator cuff tendinopathy, tear or impingement, subacromial bursa fluid or wall thickening, abnormalities of the long head of the biceps tendon, or calcification Seventy-four patients underwent a subacromial corticosteroids injection with methylprednisolone, ultrasound guided. Treatment efficacy was evaluated a one month, six, 12 and 18 months. The primary outcome measure was a 10-cm VAS for shoulder pain intensity. The mean age was 67.9±12.4 years and the men disease duration was 25.5±14.5 months. <h3>Results</h3> Right shoulder was more commonly involved (74%). Rotator cuff tendinopathy was found in 67%, subacromial bursa fluid in 38%, calcification in 27%, signs of impingement in 42.8%, adhesive capsulitis in 8.9%, partial tears of rotator cuff in 12.5%. Median visual analog scale (VAS) pain score was 8,4 before treatment, 7.7, 5.4 and 4.1 at 6, 12 and 18 months after treatment, respectively. The patients with subacromial bursa fluid showed a significantly greater improvement in VAS scores compared with patients with not had (p&lt;0.05). In patients with nocturnal pain the treatment response was better (p=0,06). In patients with calcifications the response was worse (p&lt;0,05). The patientsunderwent a subacromial corticosteroids injections in first 6 months of disease duration had a better response (p&lt;0, 05) in the shoulder pain reduction. There were no complications observed. <h3>Conclusions</h3> The subacromial steroid injection was more effective in patients with subacromial bursa fluid, with nocturnal pain and in the first six months of disease. Patients with calcification in ultrasound had a poor response. The subacromial steroid injection was safe, there were no complications observed <h3>Disclosure of Interest</h3> None Declared
Abstract 2877: TRAMP-injected mice fed a no-carbohydrate ketogenic diet demonstrate prolonged survival and decreased tumor volumes compared to mice fed western or low-fat diets
Authors: Brian M. Whitley, Elizabeth M. Masko, Jean A. Thomas, Howard S. Kim, Susan A. Poulton, Tameika E. Phillips, Stephen J. Freedland
Journal: Cancer Research (2010)

Abstract Introduction and Objective: In multiple previous studies, we have shown that mice injected with subcutaneous prostate cancer cells (LNCaP or LAPC-4) and fed a no-carbohydrate ketogenic diet (NCKD, 84% fat, 0% carbohydrate, 16% protein) have significantly decreased tumor volume and significantly prolonged survival, compared to mice fed a western diet (WD, 40% fat, 44% carbohydrate, 16% protein). All previous studies utilized a human prostate cancer cell line, requiring the use of immunodeficient mice. We sought to replicate these previous studies to determine whether diet affected tumor progression and survival in an immunocompetent model. Methods: In this treatment model, 75 male C57bl/6 mice were initially fed WD ad libitum for a period of 14 days. After this 14 day period, all mice were injected subcutaneously with 2.5×105 TRAMP cells and randomized to one of three diets: WD, NCKD, or low-fat diet (LF, 12% fat, 72% carbohydrate, 16% protein). Mice receiving LF diet were fed ad libitum, and served as the reference group in paired-feeding protocols for mice receiving WD and NCKD. Tumor volumes were assessed twice weekly, and mice were sacrificed when tumor volumes reached 1000mm3. Survival was calculated using a Log-rank test and tumor volumes were compared among dietary groups using Kruskal-Wallis test for significance. Results: Mice fed a NCKD demonstrated a trend towards decreased tumor volumes compared to mice fed WD and LF. Median tumor volume at study day 66 for mice fed WD, LF, and NCKD were 1091.2 mm3, 1082.9 mm3, and 661.5mm3 respectively. While the tumor volumes were smaller in mice fed NCKD versus LF or WD, these differences did not reach statistical significance (WD vs. NCKD, p=0.06; LF vs. NCKD, p=0.12). There was no significant difference between tumor volumes among mice fed WD compared to LF (p=0.95). Additionally, a trend towards improved survival was seen in mice fed NCKD vs. WD (p=0.09). Conclusion: This study in an immunocompetent xenograft model supports the findings of multiple previous studies. Mice fed a NCKD demonstrated a trend towards prolonged survival and decreased tumor volume compared to mice fed WD. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 2877.
A rare case of gastric carcinoma with interspersed endocrine
Authors: Hyodo Takafumi, Hyodo Naoko
Journal: Endoscopy (2011)

We report a rare case of gastric carcinoma with interspersed endocrine cells. A 77-year old man underwent sigmoidectomy for an advanced sigmoid carcinoma [well differentiated adenocarcinoma, pT4(se), ly1, v3, pN0, pM0] at our hospital on August 15, 2005. The regular postoperative follow-up examination by an upper endoscopy revealed a gastric polypoid lesion, on August 11, 2009. The findings showed an atypical submucosal tumor of about 20mm with focal irregular glandular features on surface, defined by NBI (narrow-band imaging) endoscopy. EUS demonstrated a submucosal heterogenous hypoechoic mass, 10mm, a little distant from the proper muscular layer, including internal duct structures. The biopsy specimen suggested moderately differentiated adenocarcinoma with endocrine differentiation or mixed with carcinoid tumor. After admission, the submucosal lesion was safely removed by the ESD (endoscopic submucosal resection) method, with submucosal injection of hyaluronic acid (HA) just between the mass and the proper muscular layer, guided by a convex type echoendoscope. The histological findings of the resected specimen evidenced an early gastric carcinoma with interspersed endocrine cells: [moderately differentiated adenocarcinoma, sm2, ly0, v2, vertical margins (-), lateral margins (suspected partly +)] with interspersed endocrine cells. The immunohistochemical findings revealed intermixing of cancer cells and endocrine cells. The additional operation evidenced no residual lesions later. In this case, EUS was not so useful for the precise diagnosis, but a powerful tool for submucosal injection of HA to carry out ESD safely.
Abstract 2476: Acetylated Survivin functions in DNA damage repair
Authors: Zachary A. Cooper, Matthew Riolo, Michael P. Holloway, Rachel A. Altura
Journal: Cancer Research (2011)

Abstract Survivin is an oncogenic protein that participates in cell division and inhibits apoptosis in cancer cells. These functions are dependent on its interaction with partner proteins within distinct subcellular compartments. Survivin is highly expressed in malignant tumors yet minimally expressed in normal tissues, making it an attractive target for molecular therapy. Inhibition of Survivin function enhances tumor cell sensitivity to radiation, the mechanism of which has been reported to result from a disruption of DNA-double-strand break repair processes. Recently, we demonstrated that Survivin is post-translationally modified by acetylation at numerous lysine residues, one of which is responsible for its subcellular transport. Acetylation at Lys-129 facilitates Survivin homodimerization which prevents its binding to the CRM1 nuclear export protein, inhibiting its translocation from the nucleus to the cytoplasm. The object of this study was to determine the potential relationship between Survivin acetylation and its function in nuclear repair processes. To elucidate the association between Survivin acetylation, nuclear localization and DNA double-strand break repair we subjected HeLa cells to 4Gy γXRT and examined Survivin acetylation at serial time points (20, 40, 60 min) after irradiation. An immediate deacetylation of Survivin was observed at 20 minutes, followed by an increase in both global acetylation and acetylation at Lys-129 at 40 minutes. The increase in Lys-129 acetylation correlated with its nuclear accumulation, as demonstrated by indirect immunofluorescence staining and immunoblotting after subcellular fractionation. Acetylated Survivin was found in endogenous immunoprecipitants with the DNA damage repair protein, Ku70, following γ-irradiation. Indirect immunoflourescence revealed co-localization of Ku70 and acetylated Survivin within the nucleus at similar time points after irradiation suggesting that Survivin acetylation may be required for Ku70 complex formation within the nucleus. These results implicate acetylated Survivin as a regulator of DNA damage repair through the Ku70 DNA repair pathway and further our understanding of Survivin function within the nuclear compartment of cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 2476. doi:10.1158/1538-7445.AM2011-2476
THU0370 Is Chills an Independent Predictor Factor for Familial Mediterranean Fever Severity Score?
Authors: C. Bes, Y. Çağatay, T. Ulaş, M. Soy
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Familial Mediterranean fever (FMF) is an autosomal recessive disorder characterized by paroxysmal episodes of fever and serosal inflammation. The classical presentation is fever and severe recurrent abdominal pain due to serositis that lasts for one to three days and the resolves spontaneously. Some people experience chills prior to the onset of fever. <h3>Objectives</h3> In this study, we aimed to determine whether the chills is the predictor factor or not for the severity score in patients with FMF. <h3>Methods</h3> Consecutively 57 patients diagnosed with FMF were recruited for this cohort study, and the patients were classified according to the Tel-Hashomer Severity Score. Pearson correlation analysis was made to find the relationships between disease severity score and clinical features of the patients. A linier regression analysis was performed to identify the possible predictors of the FMF severity score. <h3>Results</h3> The mean age was 30.72±9.99 years, 54.4% was male and 45.6% was female. There was a mean period of 16.87±10.59 years from disease onset to diagnosis. Delayed in the diagnosis time was 13.10±11.00. Patients9 clinical features included peritonitis (96.5%), fever (82.5%), arthritis (38.6%), pleuritis (14%), chills (35.1%), and erysipelas-like erythema (15.8%). Thirty three percent of the patients had a history of appendicitis. Amyloidosis was not remarkably frequent in our patients (1.8%). Genetic analysis of 57 patients revealed that M694V was the most frequent mutation (70.2%), followed by M680I (21%) and V726A (21.2%). In Pearson correlation analysis chills were correlated with fever (r=0.339, p=0.01), and a history of appendicitis (r=0.416, p=0.001). Linier regression analysis showed that chill is the independent predictor factor of the FMF severity score (Adjusted r<sup>2</sup>=0.414, Beta=0.462, Std error=2.127, p=0.003). <h3>Conclusions</h3> Our study showed that chills would be a predictor factor to demonstrate the FMF severity score. Future large-scale multicenter randomized controlled studies are needed and warranted to clarify our results. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5408
AB0453 Response to TOCILIZUMAB in Rheumatoid Arthritis is not Influenced by the Body Mass Index of the Patient
Authors: Y.-M. Pers, M. Godfrin-Valnet, J. Lambert, C. Fortunet, E. Constant, T. Mura, B. Pallot-Prades, C. Jorgensen, J.-F. Maillefert, H. Marotte, D. Wendling, P. Gaudin
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Objectives</h3> To assess relationship between body mass index (BMI) and efficacy of tocilizumab (TCZ) in rheumatoid arthritis (RA) patients. <h3>Methods</h3> We conducted a retrospective study of the use of TCZ in patients with RA followed by five academic hospitals in France. The efficacy of TCZ was evaluated at 6 months by the European League Against Rheumatism (EULAR) response. Univariate and multivariate logistic regressions were performed adjusting for age, sex, disease duration, C-Reactive protein, erythrocyte sedimentation rate, presence of erosive lesions, rheumatoid factor and anti-citrullinated peptide antibodies positivity, disease duration, disease activity score, concomitant therapy by disease modifying anti-rheumatic drugs. <h3>Results</h3> Among 222 RA patients treated by TCZ, 58.5% had a low BMI&lt;25kg/m<sup>2</sup>, 26% had an intermediate BMI between 25-30kg/m<sup>2</sup>, and 15.5% had a high BMI&gt;30kg/m<sup>2</sup>. No significant association between BMI and response to TCZ at 6 months was found after adjustment for potential confounding factors (OR 0.47; 95%CI [0.18; 1.23], p=0.12 and OR 1.56 95%CI [0.42; 5.67], p=0.49 for BMI=25-30kg/m<sup>2</sup> and BMI&gt;30kg/m<sup>2</sup> respectively compared to BMI&lt;25kg/m<sup>2</sup>). <h3>Conclusions</h3> Response to TCZ in RA patients is not influenced by the baseline BMI, in contrast to anti-TNF drugs. Future research should assess these differences prospectively for better comparisons. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.1508
CORONARY CALCIUM SCORE VERSUS CHRONOLOGICAL AGE FOR CARDIOVASCULAR RISK PREDICTION IN THE ELDERLY: THE FRAMINGHAM OFFSPRING STUDY, THE MULTI-ETHNIC STUDY OF ATHEROSCLEROSIS, AND THE CARDIOVASCULAR HEALTH STUDY
Authors: Yuichiro Yano, Hongyan Ning, Christopher O’Donnell, Lewis Kuller, Oscar Franco, Raimund Erbel, Ralph D’Agostino, Khurram Nasir, Anne Newman, Ron Blankstein, Maryam Kavousi, Stefan Möhlenkamp, Nils Lehmann, Amir-Abbas Mahabadi, Udo Hoffmann, Joseph Massaro, Joao Lima, Kiang Liu, Donald Lloyd-Jones, Philip Greenland
Journal: Journal of the American College of Cardiology (2016)
Western Washington Randomized Trial of Intracoronary Streptokinase in Acute Myocardial Infarction
Authors: J. Ward Kennedy, James L. Ritchie, Kathryn B. Davis, James K. Fritz
Journal: New England Journal of Medicine (1983)

Two hundred fifty patients were enrolled in a multicenter, community-based study of the efficacy of intracoronary streptokinase thrombolysis in acute myocardial infarction; 134 were randomly assigned to streptokinase therapy and 116 were controls. All patients underwent left ventricular angiography and coronary arteriography before the random assignment. The mean time from the onset of symptoms to hospitalizaron was 134±144 minutes (S.D), and the mean time to random assignment was 276±185 minutes. Coronary reperfusion was achieved in 68 per cent of the streptokinase-treated group. The overall 30-day mortality was 18 (7.2 per cent); there were five deaths in the streptokinase-treated group (3.7 per cent) and 13 in the control group (11.2 per cent, P<0.02). Fifteen of the 18 deaths occurred in patients with anterior infarction. Intracoronary streptokinase therapy resulted in a nearly threefold reduction in the 30-day mortality after hospitalization for acute myocardial infarction. (N Engl J Med 1983; 309:1477–82.)